New Study Links Weight Loss Drugs to Reduced Dementia Risk

A major study suggests that popular weight loss medications might significantly lower the risk of developing dementia. Researchers from Ireland investigated clinical trials involving nearly 165,000 individuals using drugs aimed at lowering glucose levels and treating diabetes.

While the majority of glucose-lowering therapies showed no meaningful effect on dementia risk, those using GLP-1 agonists, like Ozempic and Wegovy, were found to be 45% less likely to develop dementia at some point compared to users of other medications.

The exact mechanism isn’t completely clear. However, the researchers suspect that the active compounds in these drugs—chiefly semaglutide and tirzepatide—may help reduce inflammation in the brain. Neuroinflammation is believed to harm neurons and disrupt communication in areas responsible for memory, which can lead to dementia symptoms.

Additionally, GLP-1 agonists might help decrease the presence of toxic amyloid and tau proteins, which are commonly associated with dementia. The team theorizes that medications like Ozempic could potentially prevent both diabetes and dementia, two conditions increasingly prevalent in the U.S.

Dr. Catriona Reddin, the lead author of the study from the University of Galway, emphasized the importance of this research in understanding how certain diabetes medications might affect brain health. She noted that while diabetes is a known risk factor for dementia, the role of glucose-lowering treatments in preventing cognitive decline has been somewhat ambiguous.

The study follows a related analysis from the University of Florida that tracked 400,000 Americans on glucose-lowering drugs, revealing a 33% reduction in dementia risk for GLP-1 users compared to other treatments. In the U.S., around 8 million adults live with some form of dementia, with 500,000 new diagnoses each year. Interestingly, about one in eight U.S. adults has reported using Ozempic or similar drugs at least once for diabetes or weight loss.

This new research, published in JAMA Neurology, reviewed 26 studies focused on the correlation between GLP-1 agonist usage and dementia risk, involving 164,531 participants, predominantly men, with an average age of 64 and a follow-up period of approximately 31 months.

While this investigation offers promising insights, it acknowledges limitations, such as insufficient data on specific dementia subtypes like vascular and Lewy body dementia. Overall, there seems to be potential for GLP-1 agonists to lower inflammation a key factor in dementia development. Observations also suggest these drugs may enhance blood vessel protection, possibly reducing the risk of vascular dementia.

In recent reports, the Alzheimer’s Association indicated that Alzheimer’s disease, the most prevalent form of dementia, has seen a 25-year consecutive increase in diagnosis rates in the U.S. Meanwhile, diabetes has now affected about 12% of Americans, with numbers tripling in the last 30 years.